These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee. Emerg Infect Dis; 1995; 1(2):66. PubMed ID: 8979849 [No Abstract] [Full Text] [Related]
6. The need for accuracy in performing vancomycin intermediate resistant Staphylococcus aureus (VISA) and hetero--VISA detection methods. Wootton M Int J Antimicrob Agents; 2006 Dec; 28(6):586. PubMed ID: 17049817 [No Abstract] [Full Text] [Related]
7. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Sader HS; Jones RN Clin Infect Dis; 2006 Sep; 43(6):798-9; author reply 799-800. PubMed ID: 16912964 [No Abstract] [Full Text] [Related]
8. Enterococcal resistance--an overview. Marothi YA; Agnihotri H; Dubey D Indian J Med Microbiol; 2005 Oct; 23(4):214-9. PubMed ID: 16327115 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H; J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703 [TBL] [Abstract][Full Text] [Related]
11. A new class of anti-MRSA and anti-VRE agents: preparation and antibacterial activities of indole-containing compounds. Yamamoto Y; Kurazono M Bioorg Med Chem Lett; 2007 Mar; 17(6):1626-8. PubMed ID: 17254785 [TBL] [Abstract][Full Text] [Related]
13. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Pillai SK; Gold HS; Sakoulas G; Wennersten C; Moellering RC; Eliopoulos GM Antimicrob Agents Chemother; 2007 Jun; 51(6):2223-5. PubMed ID: 17404001 [TBL] [Abstract][Full Text] [Related]
14. Rapid detection of Staphylococcus aureus strains having reduced susceptibility to vancomycin using a chemiluminescence-based drug-susceptibility test. Tajima Y; Komatsu M; Ito T; Hiramatsu K J Microbiol Methods; 2007 Sep; 70(3):434-41. PubMed ID: 17655957 [TBL] [Abstract][Full Text] [Related]
15. The misuse of vancomycin. Skae CC Pediatr Rev; 2003 Jul; 24(7):249-50; discussion 249-50. PubMed ID: 12837963 [No Abstract] [Full Text] [Related]
16. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538 [TBL] [Abstract][Full Text] [Related]
17. Synthesis of rigidly-linked vancomycin dimers and their in vivo efficacy against resistant bacteria. Lu J; Yoshida O; Hayashi S; Arimoto H Chem Commun (Camb); 2007 Jan; (3):251-3. PubMed ID: 17299629 [TBL] [Abstract][Full Text] [Related]
19. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. Scheinfeld N J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167 [TBL] [Abstract][Full Text] [Related]
20. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in a patient with erythrodermic psoriasis. Bakri FG; Al-Hommos NA; Shehabi A; Naffa RG; Cui L; Hiramatsu K Scand J Infect Dis; 2007; 39(5):457-60. PubMed ID: 17464871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]